Beta Bionics Chief Commercial Officer Mark Hopman sold 30,779 shares at $20.13 each on 2026-09-16. The post-sale position was 56,479 shares in Beta Bionics, and the transaction equalled about 35.3% of his prior holding.

Key Highlights

  • Mark Hopman’s transaction represented about 35.3% of his prior Beta Bionics shareholding.
  • The Beta Bionics executive retained 56,479 shares after the transaction.
  • The reported trade was priced at $20.13 per share.

Mark Hopman, the company’s Chief Commercial Officer, sold 30,779 shares on 16 September 2026 at $20.13 each, leaving him with 56,479 shares.

Beta Bionics (NASDAQ: BBNX) Sale Details

The transaction occurred on 16 September 2026, with each of the 30,779 shares priced at $20.13. His remaining position was 56,479 Beta Bionics (NASDAQ: BBNX) shares after the sale.

35.3% of Prior Holding Sold

About 35.3% is the stated measure for the portion of Hopman’s prior holding represented by the transaction. The percentage refers to the position before the sale, while the share count describes what he held afterward.